Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.1% – Here’s Why

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s stock price fell 7.1% during trading on Monday . The stock traded as low as $24.12 and last traded at $24.5730. 673,841 shares were traded during trading, a decline of 46% from the average daily volume of 1,238,818 shares. The stock had previously closed at $26.44.

Analyst Upgrades and Downgrades

CAPR has been the topic of several recent analyst reports. LADENBURG THALM/SH SH upgraded shares of Capricor Therapeutics to a “strong-buy” rating in a research note on Thursday, June 25th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the company an “overweight” rating in a research report on Friday, March 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Piper Sandler reiterated an “overweight” rating and issued a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research note on Wednesday, May 13th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Capricor Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $53.67.

Capricor Therapeutics Price Performance

The stock has a 50 day moving average of $29.58 and a 200 day moving average of $28.35. The firm has a market cap of $1.39 billion, a P/E ratio of -10.38 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). On average, research analysts predict that Capricor Therapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Insider Activity at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of Capricor Therapeutics stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $30.38, for a total transaction of $732,158.00. Following the transaction, the chief financial officer directly owned 11,223 shares of the company’s stock, valued at approximately $340,954.74. This trade represents a 68.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $32.00, for a total transaction of $240,928.00. Following the completion of the sale, the director owned 7,529 shares of the company’s stock, valued at approximately $240,928. The trade was a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 57,529 shares of company stock valued at $1,792,586. 9.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CAPR. Vanguard Group Inc. boosted its holdings in Capricor Therapeutics by 16.1% during the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares during the period. Suvretta Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $51,533,000. Tang Capital Management LLC bought a new stake in Capricor Therapeutics in the fourth quarter valued at approximately $49,062,000. RA Capital Management L.P. purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at approximately $43,516,000. Finally, Geode Capital Management LLC grew its holdings in shares of Capricor Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after purchasing an additional 55,766 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.